Last reviewed · How we verify
IMC-001 and Optimal medical treatment
IMC-001 and Optimal medical treatment is a Small molecule drug developed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | IMC-001 and Optimal medical treatment |
|---|---|
| Sponsor | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMC-001 and Optimal medical treatment CI brief — competitive landscape report
- IMC-001 and Optimal medical treatment updates RSS · CI watch RSS
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. portfolio CI
Frequently asked questions about IMC-001 and Optimal medical treatment
What is IMC-001 and Optimal medical treatment?
IMC-001 and Optimal medical treatment is a Small molecule drug developed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc..
Who makes IMC-001 and Optimal medical treatment?
IMC-001 and Optimal medical treatment is developed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (see full ImmuneOnco Biopharmaceuticals (Shanghai) Inc. pipeline at /company/immuneonco-biopharmaceuticals-shanghai-inc).
What development phase is IMC-001 and Optimal medical treatment in?
IMC-001 and Optimal medical treatment is in Phase 2.